Andrew Hotchkiss becomes CCO at Immunocore

Company: Immunocore Ltd

Appointee: Andrew Hotchkiss


United Kingdom

Immunocore Ltd, which is developing cancer therapies based on T cell receptors, has appointed Andrew Hotchkiss as its chief commercial officer. Mr Hotchkiss joins the UK company from Eli Lilly & Co where was senior vice president for digital ventures and before that, head of the US company’s international oncology business unit. He holds a degree in biochemistry from University College Cardiff in the UK.

Immunocore announced the appointment on 4 October 2017.

Copyright 2017 Evernow Publishing Ltd